Adicet Bio (ACET) Total Current Liabilities (2017 - 2026)

Adicet Bio's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 11.25% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $18.3 million (up 11.25% YoY), while the FY2025 annual figure was $21.5 million, up 11.03% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $18.3 million, down from $21.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $21.5 million in Q4 2025, with the low at $10.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $18.3 million (2026), against an average of $18.0 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 58.7% in 2022, then jumped 73.97% in 2023.
• Adicet Bio's Total Current Liabilities stood at $19.7 million in 2022, then declined by 2.13% to $19.3 million in 2023, then grew by 0.54% to $19.4 million in 2024, then advanced by 11.03% to $21.5 million in 2025, then decreased by 15.02% to $18.3 million in 2026.
• Business Quant data shows ACET's Total Current Liabilities at $18.3 million in Q1 2026, $21.5 million in Q4 2025, and $18.9 million in Q3 2025.